HRP20241508T1 - Kombinirana terapija sorafenibom ili regorafenibom i fosforamidatskim prolijekom troksacitabina - Google Patents
Kombinirana terapija sorafenibom ili regorafenibom i fosforamidatskim prolijekom troksacitabina Download PDFInfo
- Publication number
- HRP20241508T1 HRP20241508T1 HRP20241508TT HRP20241508T HRP20241508T1 HR P20241508 T1 HRP20241508 T1 HR P20241508T1 HR P20241508T T HRP20241508T T HR P20241508TT HR P20241508 T HRP20241508 T HR P20241508T HR P20241508 T1 HRP20241508 T1 HR P20241508T1
- Authority
- HR
- Croatia
- Prior art keywords
- troxacitabine
- phosphoramidate prodrug
- use according
- sorafenib
- phosphoramidate
- Prior art date
Links
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 title claims 20
- 239000000651 prodrug Substances 0.000 title claims 20
- 229940002612 prodrug Drugs 0.000 title claims 20
- RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 title claims 20
- 229950010147 troxacitabine Drugs 0.000 title claims 20
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 title claims 9
- 239000005511 L01XE05 - Sorafenib Substances 0.000 title claims 9
- 229960003787 sorafenib Drugs 0.000 title claims 9
- 239000002138 L01XE21 - Regorafenib Substances 0.000 title claims 2
- 229960004836 regorafenib Drugs 0.000 title claims 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 title claims 2
- 238000002648 combination therapy Methods 0.000 title 1
- 206010027476 Metastases Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- -1 2-propylpentyl Chemical group 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027457 Metastases to liver Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650274 | 2016-03-02 | ||
| SE1651204 | 2016-09-08 | ||
| EP17760400.6A EP3423061B1 (en) | 2016-03-02 | 2017-02-28 | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
| PCT/SE2017/050186 WO2017151044A1 (en) | 2016-03-02 | 2017-02-28 | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241508T1 true HRP20241508T1 (hr) | 2025-01-03 |
Family
ID=59744330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241508TT HRP20241508T1 (hr) | 2016-03-02 | 2017-02-28 | Kombinirana terapija sorafenibom ili regorafenibom i fosforamidatskim prolijekom troksacitabina |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10456413B2 (enExample) |
| EP (1) | EP3423061B1 (enExample) |
| JP (1) | JP6968080B2 (enExample) |
| KR (1) | KR102703122B1 (enExample) |
| CN (2) | CN111956646B (enExample) |
| AU (2) | AU2017227516B2 (enExample) |
| CA (1) | CA3014769C (enExample) |
| ES (1) | ES2987989T3 (enExample) |
| HR (1) | HRP20241508T1 (enExample) |
| HU (1) | HUE068940T2 (enExample) |
| MY (1) | MY198140A (enExample) |
| PL (1) | PL3423061T3 (enExample) |
| RS (1) | RS66090B1 (enExample) |
| RU (1) | RU2018134336A (enExample) |
| SG (1) | SG11201806855WA (enExample) |
| WO (1) | WO2017151044A1 (enExample) |
| ZA (1) | ZA201805445B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3423061T3 (pl) | 2016-03-02 | 2024-12-16 | Medivir Aktiebolag | Leczenie skojarzone sorafenibem lub regorafenibem i amidofosforanowym prolekiem troksacytabiny |
| JP2021512875A (ja) * | 2018-02-02 | 2021-05-20 | カースゲン セラピューティクス カンパニー リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． | 細胞免疫療法の組み合わせ |
| JP7337539B2 (ja) | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| CN113453685A (zh) * | 2019-02-18 | 2021-09-28 | 美迪维尔公司 | 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法 |
| US20240024342A1 (en) * | 2020-04-15 | 2024-01-25 | Medivir Ab | Miv-818/lenvatinib combination therapy for liver cancer |
| KR20210156389A (ko) | 2020-06-17 | 2021-12-27 | 재단법인대구경북과학기술원 | 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물 |
| IT202000022636A1 (it) | 2020-09-25 | 2022-03-25 | Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter | “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma” |
| WO2024205477A1 (en) * | 2023-03-30 | 2024-10-03 | Medivir Ab | Method for treating liver cancers using fostroxacitabine bralpamide, an immune checkpoint inhibitor and a vegf antagonist |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2002030922A2 (en) * | 2000-10-13 | 2002-04-18 | Shire Biochem Inc. | Dioxolane analogs for improved inter-cellular delivery |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| DE602004011340T2 (de) | 2003-05-20 | 2008-11-06 | Bayer Healthcare Llc | Diaryl-harnstoffe mit kinasehemmender wirkung |
| NZ544920A (en) * | 2003-07-23 | 2009-11-27 | Bayer Healthcare Llc | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
| CN102671196B (zh) * | 2006-04-05 | 2014-12-03 | 诺华股份有限公司 | 用于治疗癌症的治疗剂的组合 |
| US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| CN102190616B (zh) | 2010-03-18 | 2015-07-29 | 苏州泽璟生物制药有限公司 | 一种氘代的ω-二苯基脲的合成及生产的方法和工艺 |
| EP4140487A1 (en) | 2012-04-13 | 2023-03-01 | Epizyme Inc | Combination therapy for treating cancer |
| CN103570613B (zh) | 2012-07-18 | 2016-06-15 | 苏州泽璟生物制药有限公司 | 氘代ω-二苯基脲或其盐的多晶型物 |
| WO2014022116A2 (en) | 2012-07-28 | 2014-02-06 | Calitor Sciences, Llc | Substituted pyrazolone compounds and methods of use |
| WO2014047199A1 (en) * | 2012-09-19 | 2014-03-27 | The Research Foundation For The State University Of New York | Novel prodrugs for selective anticancer therapy |
| EP3074399A1 (en) * | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| BR112016011949A8 (pt) * | 2013-11-27 | 2020-04-28 | Idenix Pharmaceuticals Llc | composto, composição farmacêutica, e, uso dos mesmos |
| SG10201911558UA (en) * | 2014-08-25 | 2020-01-30 | Medivir Ab | Dioxolane analogues of uridine for the treatment of cancer |
| PL3423061T3 (pl) * | 2016-03-02 | 2024-12-16 | Medivir Aktiebolag | Leczenie skojarzone sorafenibem lub regorafenibem i amidofosforanowym prolekiem troksacytabiny |
-
2017
- 2017-02-28 PL PL17760400.6T patent/PL3423061T3/pl unknown
- 2017-02-28 AU AU2017227516A patent/AU2017227516B2/en active Active
- 2017-02-28 CA CA3014769A patent/CA3014769C/en active Active
- 2017-02-28 KR KR1020187028361A patent/KR102703122B1/ko active Active
- 2017-02-28 HU HUE17760400A patent/HUE068940T2/hu unknown
- 2017-02-28 US US16/081,383 patent/US10456413B2/en active Active
- 2017-02-28 RS RS20241192A patent/RS66090B1/sr unknown
- 2017-02-28 WO PCT/SE2017/050186 patent/WO2017151044A1/en not_active Ceased
- 2017-02-28 ES ES17760400T patent/ES2987989T3/es active Active
- 2017-02-28 EP EP17760400.6A patent/EP3423061B1/en active Active
- 2017-02-28 CN CN202010727607.5A patent/CN111956646B/zh active Active
- 2017-02-28 SG SG11201806855WA patent/SG11201806855WA/en unknown
- 2017-02-28 HR HRP20241508TT patent/HRP20241508T1/hr unknown
- 2017-02-28 MY MYPI2018703064A patent/MY198140A/en unknown
- 2017-02-28 RU RU2018134336A patent/RU2018134336A/ru not_active Application Discontinuation
- 2017-02-28 CN CN201780014430.0A patent/CN109069509B/zh active Active
- 2017-02-28 JP JP2018545847A patent/JP6968080B2/ja active Active
-
2018
- 2018-08-15 ZA ZA2018/05445A patent/ZA201805445B/en unknown
-
2019
- 2019-08-30 US US16/557,511 patent/US10960017B2/en active Active
-
2022
- 2022-06-01 AU AU2022203761A patent/AU2022203761B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241508T1 (hr) | Kombinirana terapija sorafenibom ili regorafenibom i fosforamidatskim prolijekom troksacitabina | |
| JP2019507764A5 (enExample) | ||
| PH12018500088A1 (en) | Substituted tricyclics and method of use | |
| NZ739902A (en) | Multiligand agent for drug delivery | |
| PH12018500765A1 (en) | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | |
| WO2017079746A3 (en) | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer | |
| PH12017500797A1 (en) | Substituted chromanes and methods of use | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| MY199604A (en) | Heteroaryl substituted pyridines and methods of use | |
| IL302093A (en) | Combined therapy involving antibodies against claudin 18.2 for the treatment of cancer | |
| JP2018507197A5 (enExample) | ||
| MX393599B (es) | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco | |
| NZ726366A (en) | Syk inhibitors | |
| MX2017015591A (es) | Piridinas sustituidas y metodo de uso. | |
| MX2018004364A (es) | Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso. | |
| MX2022001863A (es) | Metodos para tratar los tumores del estroma gastrointestinal. | |
| NZ722345A (en) | Pyrazolone compounds and uses thereof | |
| HRP20230523T1 (hr) | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta | |
| JP2016502981A5 (enExample) | ||
| TN2017000168A1 (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| EP4364807A3 (en) | Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| JP2017516827A5 (enExample) | ||
| HRP20221319T1 (hr) | Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka |